Chronologic Age/Bone Age Ratio of Subjects at End of Double-blind Treatment Period, n (%)Total, n (%)b
LowNormalHigh
CIC40
    Low (baseline)6 (3.2)3 (1.6)0 (0.0)9 (4.9)
    Normal (baseline)15 (8.1)115 (62.2)8 (4.3)138 (74.6)
    High (baseline)a0 (0.0)16 (8.6)22 (11.9)38 (20.5)
    Totalc21 (11.4)134 (72.4)30 (16.2)185 (100.0)
CIC160
    Low (baseline)3 (1.7)1 (0.6)0 (0.0)4 (2.3)
    Normal (baseline)11 (6.3)119 (68.0)2 (1.1)132 (75.4)
    High (baseline)a0 (0.0)16 (9.1)23 (13.1)39 (22.3)
    Totalc14 (8.0)136 (77.7)25 (14.3)175 (100.0)
Placebo
    Low (baseline)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
    Normal (baseline)11 (6.2)122 (68.9)7 (4.0)140 (79.1)
    High (baseline)a0 (0.0)16 (9.0)21 (11.9)37 (20.9)
    Totalc11 (6.2)138 (78.0)28 (15.8)177 (100.0)
  • Analysis included only patients from the mITT population who had valid baseline and postbaseline measurements.

  • a A high chronologic age/bone age ratio is indicative of growth retardation.

  • b Column indicates the total number (%) of subjects with the specified chronologic age/bone age ratio at baseline.

  • c Row indicates the total number (%) of subjects with the specified chronologic age/bone age ratio at the end of the double-blind treatment period.